Preimplantation genetic testing (PGT) refers to genetic testing performed on an embryo in the early stages of embryonic development. PGT can be used to identify embryos affected by genetic abnormalities that could increase the chance of miscarriage or increase the chance of a pregnancy affected by chromosomal conditions (ie. cystic fibrosis, Tay-Sachs disease, hemophilia). Preimplantation genetic testing and the subsequent transfer of a single, euploid (undefinednormalundefined) embryo increases the chance of successful implantation and, ultimately, increases the chance of a successful pregnancy.
PGT requires the removal of a small number of cells from the developing embryo in a process called an undefinedembryo biopsy.undefined The biopsy is performed by skilled embryologists at NYU Langone Fertility Center. The embryos are then frozen and stored onsite at NYU Langone Fertility Center, while the sample of cells removed (undefinedembryo cultureundefined) is sent to a genetic testing lab to perform PGT analysis.
NYU Langone Fertility Center is proud to recognize our program director, Dr. James Grifo, former president of the Society for Assisted Reproductive Technology, as a pioneer in this field. In 1992, Dr. Grifo performed the first embryo biopsy that led to a live birth in the United States.
Nearly 30 years later, the NYU Langone Fertility Center now performs PGT on more than 75% of the embryos created during traditional
We recommend that all patients who plan to undergo IVF discuss preimplantation genetic testing with their physician. Additionally, PGT is recommended for individuals or couples with one or more of the following:
Preimplantation genetic testing for aneuploidy (PGT-A) allows us to count the number of chromosomes in the embryo culture.. Chromosomes are the structures found within cells that contain genetic material (DNA) in 23 chromosomal pairs. PGT-A analysis helps to identify any embryos affected with genetic abnormalities (ie. too many or too few chromosomes, or structural defects).
There are 4 possible results from PGT-A testing: euploid, aneuploid, mosaic, and inconclusive.
PGT-A testing and the transfer of a single, euploid (undefinednormalundefined) embryo reduces the risk of miscarriage by reducing the chance of transferring a genetically abnormal embryo. PGT-A testing also reduces the chance of multiple pregnancies (ie. twins) undefined when PGT-A testing is performed, physicians transfer a single, euploid embryo, which reduces the chance of multiple birth to 1-2%.
At NYU Langone Fertility Center, our live birth rate from PGT-A screened embryos exceeds 50%, regardless of female age at egg retrieval. Please note, however, that the incidence of genetic abnormality increases as women age: embryos created from eggs retrieved while a woman is in her 20undefineds and early 30undefineds have a 30-50% chance of exhibiting an abnormal result; when embryos are created from eggs retrieved after a woman reaches the age of 40, the percentage of abnormal embryos increases to 70-90%.
Preimplantation genetic testing for structural rearrangements (PGT-SR) is used by specific women or men who have been diagnosed with a balanced translocation, inversion, or other type of chromosomal rearrangement. In these situations, PGT-SR can increase the chance of a live birth and reduce the chance of a miscarriage by selecting embryos that are balanced (i.e. have the correct amount of chromosomal material).
Preimplantation genetic testing for monogenic disorders (PGT-M) is used by individuals or couples who are at high risk for having a pregnancy with a specific inherited disease.
PGT-M uses various customized approaches to test for specific genetic variants (mutations) prior to implantation, in order to reduce the chance for any conceived pregnancy to be affected with the associated disorder.
PGT-M is usually possible for any condition in which a specific genetic mutation has been identified in a person undergoing IVF. Some examples of conditions for which an individual or couple may be at high risk and choose to pursue PGT-M are cystic fibrosis, hereditary breast and ovarian cancer syndrome (BRCA1 or BRCA2), fragile X syndrome, Huntingtonundefineds disease, Marfan syndrome, Tay-Sachs disease, spinal muscular atrophy, and sickle cell anemia.
At NYU Langone Fertility Center, an IVF cycle with PGT begins at $15,150, not including the cost of fertility medications, anesthesia, or products and services provided by third parties. Please be aware: PGT incurs additional lab fees that are separate from NYULFC fees, these fees are paid directly to the PGT lab and may vary by lab.
Embryos are biopsied after 3-5 days of development in the laboratory and then frozen while a culture of cells is sent to the genetic testing lab for analysis. This testing takes approximately 10 days to complete.
Information gathered during Preimplantation Genetic Screening can be used to diagnose genetic abnormalities in embryos with a 98% rate of accuracy.
Once the results of Preimplantation Genetic Screening are received, patients will discuss the results and the quality of each embryo with their physician. This will help to determine which embryo will be selected for transfer. When the patient is ready, the patient may begin a Frozen Embryo Transfer (FET) Cycle.
At NYU Langone Fertility Center, we are dedicated to providing our patients with exceptional clinical care to help them build their families. Our first job is to support you, so please reach out to our team of specialists with any questions you may have about fertility care.